LIVE
NIVESH STREET_
LIVE MARKET INTELLIGENCE
NIFTY 50 25,181.80 +1.38%SENSEX 72,472.33 +1.23%BANK NIFTY 55,256.65 +1.36%INDIA VIX 14.38 -0.42%GOLD ₹1,21,540 +0.61%BTC/USD $112,480 +2.14%USD/INR 88.42 -0.08%CRUDE $84.16 +0.94%NIFTY 50 25,181.80 +1.38%SENSEX 72,472.33 +1.23%BANK NIFTY 55,256.65 +1.36%INDIA VIX 14.38 -0.42%GOLD ₹1,21,540 +0.61%BTC/USD $112,480 +2.14%USD/INR 88.42 -0.08%CRUDE $84.16 +0.94%
Live
NIFTY 5023,810.85▲ 1.58%
SENSEX76,917.85▲ 1.62%
BANK NIFTY55,540.05▲ 0.98%
NIFTY IT32,551.6▲ 0.34%
NIFTY MIDCAP16,908.3▲ 1.14%
INDIA VIX15.72▲ 1.44%
RELIANCE1,307.9▲ 0.61%
TCS2,499.1▼ 0.10%
HDFCBANK725.5▲ 3.64%
INFY1,148.1▲ 1.15%
ICICIBANK1,424.5▲ 2.67%
SBIN970.25▼ 1.70%
BHARTIARTL2,065▲ 3.77%
ITC273.9▲ 2.82%
LT3,948.2▲ 0.21%
AXISBANK1,232.7▲ 1.96%
KOTAKBANK464.65▲ 1.37%
HINDUNILVR1,962.8▲ 3.40%
Gold (24K)3,956▼ 0.34%
Silver50.02▼ 1.38%
Copper6.43▼ 1.80%
Crude Oil (Brent)103.44▼ 1.27%
Natural Gas2.87▲ 0.53%
USD/INR94.73▼ 0.18%
Bitcoin77,165.28▲ 0.64%
Ethereum2,279.22▲ 1.35%
Solana93.02▲ 1.29%
BNB697.32▼ 0.10%
XRP1.27▲ 2.07%
Cardano0.19▲ 0.97%
Dogecoin0.08▲ 1.25%
NIFTY 5023,810.85▲ 1.58%
SENSEX76,917.85▲ 1.62%
BANK NIFTY55,540.05▲ 0.98%
NIFTY IT32,551.6▲ 0.34%
NIFTY MIDCAP16,908.3▲ 1.14%
INDIA VIX15.72▲ 1.44%
RELIANCE1,307.9▲ 0.61%
TCS2,499.1▼ 0.10%
HDFCBANK725.5▲ 3.64%
INFY1,148.1▲ 1.15%
ICICIBANK1,424.5▲ 2.67%
SBIN970.25▼ 1.70%
BHARTIARTL2,065▲ 3.77%
ITC273.9▲ 2.82%
LT3,948.2▲ 0.21%
AXISBANK1,232.7▲ 1.96%
KOTAKBANK464.65▲ 1.37%
HINDUNILVR1,962.8▲ 3.40%
Gold (24K)3,956▼ 0.34%
Silver50.02▼ 1.38%
Copper6.43▼ 1.80%
Crude Oil (Brent)103.44▼ 1.27%
Natural Gas2.87▲ 0.53%
USD/INR94.73▼ 0.18%
Bitcoin77,165.28▲ 0.64%
Ethereum2,279.22▲ 1.35%
Solana93.02▲ 1.29%
BNB697.32▼ 0.10%
XRP1.27▲ 2.07%
Cardano0.19▲ 0.97%
Dogecoin0.08▲ 1.25%
MARKETS 1h ago

Emcure Pharma Q2 Results: Profit jumps 29% to Rs 325 crore

Economic Times Stocks
Published 03 Nov 2026, 01:13 pm IST
Emcure Pharma Q2 Results: Profit jumps 29%  to Rs 325 croreAgencies

The pharma company had posted a profit of Rs 251.37 crore in the year-ago period, it said in a regulatory filing.

Its revenue from operations rose to Rs 2,820.47 crore during the September quarter, up from Rs 2,269.82 crore a year earlier.

Its total expenses were higher at Rs 2,377.87 crore during the quarter under review, up from Rs 1,931.52 crore a year ago, as per the filing.

The company recorded a strong 34 per cent growth in international business to Rs 1,665.2 crore during the quarter while its domestic business rose 11.1 per cent to Rs 1,155.3 crore, according to a statement.

In its international business, Europe grew 36 per cent, Canada was up 24 per cent, while in the rest of the world markets, it showed a growth of 41.1 per cent, as per the statement.

During the April-September period (H1), the company posted a profit of Rs 617.56 crore, 32.47 per cent higher than Rs 466.16 crore in the year-ago period.

Emcure Pharmaceuticals Chairman, Managing Director and CEO Satish Mehta said, "Q2 was another strong quarter for Emcure, with broad-based growth in revenue, profitability and earnings.... We expect business momentum to sustain into H2FY27."

The shares of Emcure Pharmaceuticals settled 5.31per cent higher at Rs 1982.55 apiece on the BSE.

Originally reported by Economic Times Stocks.Source: economictimes.indiatimes.com